Clinical Trial Update: A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the SBT101 gene therapy for Adrenomyeloneuropathy (a form of X-linked adrenoleukodystrophy) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenomyeloneuropathy
• X-linked Adrenoleukodystrophy

Drugs mentioned

• SBT101

Snippet

Sponsor: SwanBio Therapeutics, Inc. | Conditions: AMN, AMN Gene Mutation | Phase 1, Phase 2 | Status: TERMINATED